Navigation Links
Vista Partners Updates Coverage on Raptor Pharmaceuticals Corp.
Date:11/2/2007

LOS ANGELES, Nov. 2 /PRNewswire-FirstCall/ -- Vista Partners announced today that it has updated coverage on Raptor Pharmaceuticals Corp. (OTC Bulletin Board: RPTP). "We believe Raptor's operational approach will serve as the template for all small cap biotechnology companies as it promotes operational efficiency, reduced operating costs and efficient allocation of human resources. Also, Raptor now has a Phase II candidate for 2008 in Convivia(TM), which will treat a large patient population in a billion dollar plus market," stated Ross Silver, Director of Research for Vista Partners. Vista Partners provides independent, equity research to institutional and individual investors, with a focus on publicly traded small capitalization companies. For more information and to download the report for free, please visit the Vista Partners website at http://www.vistap.com.

Raptor's CEO, Dr. Christopher M. Starr, is presenting at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference at The New York Palace Hotel on Monday, November 5, 2007 at 4:05 p.m. ET. A webcast of Dr. Starr's presentation, including slides, will be posted on Raptor's website, live and archived for 90 days.

About Raptor:

Raptor Pharmaceuticals Corp.'s business consists of two segments: its 100% ownership of Raptor Pharmaceutical Inc. ("Raptor Inc."), a development stage biotechnology company which bioengineers novel drug candidates and drug- targeting platforms derived from the human receptor-associated protein ("RAP") and related proteins; and its 100% ownership of Bennu Pharmaceuticals Inc., a development stage company formed to develop clinical-stage products to marketing approval and commercialization. Raptor Inc.'s preclinical programs target cancer, neurodegenerative disorders, infectious diseases and osteoporosis. HepTide(TM) is designed to utilize engineered RAP-based peptides conjugated to drugs to target their delivery to the liver. In neurodegenerative diseases, engineered RAP peptides called NeuroTrans(TM) are currently undergoing evaluation at Stanford University in cell culture and preclinical models for their ability to enhance the transport of molecules from blood to brain. In an effort to protect its novel approach, Raptor Inc. currently has five patent applications in review in the U.S., and countries in Europe and Asia, as well as two provisional patent applications licensed from Washington University. In addition, Raptor Inc. has recently submitted two new provisional patent applications in the U.S., the first of which covers a new family of RAP peptides, with the second application to further support and expand its coverage in specific disease indications.

Bennu's initial clinical program includes the treatment of aldehyde dehydrogenase ("ALDH2") deficiency. For additional information, please visit http://www.raptorpharma.com.

Contact:

Vista Partners LLC

Ross Silver

(415) 738-6229

info@vistap.com

http://www.vistap.com


'/>"/>
SOURCE Vista Partners
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Evista Not A Cure For Heart Disease
2. Spouses and other partners lower blood pressure says new research
3. Changing Partners may put Expectant Mothers at Risk
4. British Healthcare Mission Explores Partnership Possibilities With Indian Healthcare Sector
5. Partnership Between Diabetes India And Elsevier Announced
6. Betterment Of Health In Case Of Gay And Lesbian Civil Partnerships
7. Private Public Partnership To Tackle TB, In Karnataka
8. Courting HIV through Marriage or Partnership
9. Jealousy In Men Peaks When Partners Are Most Fertile
10. War Trauma Not Passed On To Partners And Children, Study
11. SRM Inst Signs Mou With Partners Health Care
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/10/2016)... ... 10, 2016 , ... "TransPanel Volume 2 is a package of fading panel ... - CEO of Pixel Film Studios. , TransPanel Volume 2 is a set ... set of versatile transitions features presets with up to 4 panels with complementary line ...
(Date:12/9/2016)... ... 2016 , ... Groth Family Insurance, a Washington-based firm offering ... a charity drive to support the family of Cindy Hendrickson, a local mother ... On October 29th of this year, Cindy Hendrickson swerved to avoid an oncoming ...
(Date:12/9/2016)... ... December 09, 2016 , ... ... its 10th anniversary with the grand opening of the Sober College Robert Pfeifer ... spanned two days, December 2-3, and was attended by an overwhelming amount of ...
(Date:12/9/2016)... ... December 09, 2016 , ... "I had a terrible time trying to ... "I thought that if the nebulizer had a more child-friendly design, then children would ... He developed the patent-pending NEBY to avoid the need to deliver medication via a ...
(Date:12/8/2016)... ... December 08, 2016 , ... Russ DiGilio ... the first national #QuackGivesBack campaign which supported local breast cancer organizations during National ... Quack Gives Back initiative, and we’re very pleased with the participation ...
Breaking Medicine News(10 mins):
(Date:12/9/2016)... , Dec 9, 2016 Research and ... Market 2016-2020" report to their offering. ... The report forecasts the global optical ... period 2016-2020. The report covers the present scenario ... 2016-2020. To calculate the market size, the report considers the revenue ...
(Date:12/9/2016)... 9, 2016 Mitsubishi Tanabe Pharma Corporation (Head ... Director, CEO: Dr. Masayuki Mitsuka ) has presented ... given edaravone intravenously in 10-14 day cycles for 48 ... the ALS Functional Rating Scale-Revised (ALSFRS-R). The data were ... ALS/MND in Dublin, Ireland . ...
(Date:12/9/2016)... -- Research and Markets has announced the addition of ... offering. ... global travel vaccines market to grow at a CAGR of 6.83% ... scenario and the growth prospects of the global travel vaccines market ... revenue generated from the sales of various vaccines administered to actively ...
Breaking Medicine Technology: